Bristol-Myers, Ono Pharmaceutical sales and marketing update

The U.K.’s NICE issued draft guidance recommending against Opdivo nivolumab from Bristol-Myers to treat advanced renal cell carcinoma (RCC) after prior therapy -- its approved indication. The committ...